Anti-GD2 ADC M3554 in Advanced Solid Tumors
Phase 1
52
about 3.4 years
18+
3 sites in MA, NY, TX
What this study is about
This trial is testing a new treatment, M3554, for advanced solid tumors. The goal is to determine the best dose and evaluate its safety and how well it fights cancer cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take M3554
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)
Secondary: Change from Baseline in Corrected QT Interval (QTc) Interval, Duration of Response (DoR) According to RECIST Version 1.1 or RANO 2.0 as Assessed by Investigator, Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 as Assessed by Investigator, Pharmacokinetic (PK) Plasma Concentrations of M3554, Progression-free Survival (PFS) According to RECIST Version 1.1 or RANO 2.0 as Assessed by Investigator
Oncology